-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $10

Benzinga·12/17/2025 17:45:52
语音播报
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $9 to $10.